<p>However, the Prime Editing complex is relatively large, posing challenges for therapeutic delivery<ahref="#desc-three"><sup>3</sup></a>. Additionally, Prime Editing has been shown to be relatively inefficient in terms of gene editing rates, which could limit its therapeutic utility<ahref="#desc-four"><sup>4</sup></a>. Our project aims to enhance the Prime Editing approach by miniaturizing its components. Fanzor, a recently discovered eukaryotic endonuclease, performs functions similar to Cas9, a crucial part of the Prime Editing complex, but is significantly smaller. We aim to substitute Cas9 with Fanzor. </p>